ArticleThe Prostate2017
Reduced number of CD169
Article in The Prostate, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- CD169 Expression in Lymph Nodes is Associated with Increased Infiltration of CD8Journal of immunology research · 2024Pooled it
- Prognostic value of CD169-positive macrophages in various tumors: a meta-analysis.Bioengineered · 2021Pooled it
- CD169-positive macrophages in lymph nodes and the tumor microenvironment: harnessing their biology for clinical diagnosis and anticancer therapeutic strategies.Frontiers in immunology · 2026Review
- Aging potentially reduces CD169 expression in sinus macrophages of pelvic lymph nodes.Medical molecular morphology · 2025Article
- Placenta-derived trophoblast extracellular vesicles promote CD169Journal of translational medicine · 2025Article
- Exploring CD169Vaccines · 2025Review
- SIGLEC1 has the potential to be an immune-related prognostic indicator in colon adenocarcinoma: a study based on transcriptomic data and Mendelian randomization analysis.Discover oncology · 2025Article
- Anticancer immune reaction and lymph node sinus macrophages: a review from human and animal studies.Journal of clinical and experimental hematopathology : JCEH · 2024Review
- Mechanisms and characteristics of subcapsular sinus macrophages in tumor immunity: a narrative review.Translational cancer research · 2023Review
- Novel Histopathological Biomarkers in Prostate Cancer: Implications and Perspectives.Biomedicines · 2023Review
- CD169Cancer medicine · 2023Article
- Breast cancer associated CD169Frontiers in immunology · 2023Article
- Reprogramming of sentinel lymph node microenvironment during tumor metastasis.Journal of biomedical science · 2022Review
- Rat prostate tumors induce DNA synthesis in remote organs.Scientific reports · 2022Article
- The intriguing roles of Siglec family members in the tumor microenvironment.Biomarker research · 2022Review
- Article
- The pre-metastatic niche in lymph nodes: formation and characteristics.Cellular and molecular life sciences : CMLS · 2021Review
- High-grade tumours promote growth of other less-malignant tumours in the same prostate.The Journal of pathology · 2021Article
- Functions of CD169 positive macrophages in human diseases (Review).Biomedical reports · 2021Review
- A Myeloid Signature-Based Nomogram Predicts the Postoperative Recurrence of Intrahepatic Cholangiocarcinoma.Frontiers in molecular biosciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor-derived antigens are captured by CD169
methodsCD169 expression was measured with immunohistochemistry in metastasis-free regional LNs from 109 prostate cancer patients treated with prostatectomy (January 1996 to April 2002). Possible associations of CD169 expression with PSA-relapse, prostate cancer death, Gleason score, and other clinical data were assessed using Kaplan-Meier survival- and Cox regression analysis. In addition, the Dunning rat prostate tumor model was used to examine CD169 expression in pre-metastatic LNs draining either highly metastatic MatLyLu- or poorly metastatic AT1-tumors.
resultsIn patients with low CD169 immunostaining in metastasis-free regional LNs, 8 of the 27 patients died from prostate cancer compared with only three of the 82 patients with high immunostaining (P < 0.001). CD169 expression in regional LNs was not associated with PSA-relapse. Rats with highly metastatic tumors had decreased CD169 immunoreactivity in pre-metastatic regional LNs compared with rats with poorly metastatic tumors.
conclusionLow expression of CD169 in metastasis-free regional LNs indicates a reduced anti-tumor immune response. If verified in other studies, CD169 expression in regional LNs could, in combination with other factors, potentially be used as a marker of prostate cancer aggressiveness.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.